ArticleAnnals of surgical oncology2026
Molecular HPV Detection in Sentinel Lymph Nodes Using Next Generation Sequencing: Concordance with Ultrastaging and Biological Relevance in Early-Stage Cervical Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: From Histopathology to Molecular Assessment: A New Perspective on Sentinel Lymph Nodes in Cervical Cancer.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundUltrastaging of sentinel lymph nodes (SLNs) is standard for nodal assessment in early stage cervical cancer but is limited by sampling constraints and workload. Molecular detection of human papillomavirus (HPV) may identify metastatic disease. This study evaluated next generation sequencing (NGS)-based HPV detection in SLNs as a complementary approach to SLN assessment. PATIENTS AND
methodsThis prospective cohort study included 122 women with early stage cervical cancer treated with primary surgery and SLN mapping. SLNs were assessed by ultrastaging and HPV detection using an NGS-based HPV genotyping panel. A subset of patients additionally underwent polymerase chain reaction (PCR)-based HPV analysis.
resultsA total of 17 patients (13.9%) had SLN metastases identified by ultrastaging, all of which were HPV-positive by NGS. HPV read counts correlated with SLN metastasis size (Spearman's ρ = 0.73, p < 0.001). NGS additionally identified HPV in 13 patients (10.7%) with ultrastaging-negative SLNs. Compared with patients negative by both methods, these patients had significantly larger tumors (p = 0.009) and higher International Federation of Obstetrics and Gynecology (FIGO) stage (p = 0.02), while exhibiting significantly lower HPV read counts than patients positive by both ultrastaging and NGS (p = 0.03). PCR detected HPV in more SLNs than NGS.
conclusionsNGS detected HPV in all ultrastaging-confirmed SLN metastases and identified an additional subgroup of patients with molecular HPV detection despite negative ultrastaging. The association between HPV quantity, metastasis size, and adverse clinicopathological characteristics supports the biological relevance of quantitative HPV detection in SLNs. These findings warrant further evaluation of NGS as a complementary molecular biomarker for SLN assessment in larger prospective studies.
Indexed as
Identifiers
42778838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.